BRAF and central nervous system cancer: Although only 15% of canine gliomas harbored a detectable cBRAFV595E, it is of note that ~60% of canine gliomas show copy number gain of the gene, which raises the possibility that increase in BRAF gene dosage may serve as another mechanism for MAPK pathway dysregulation [47].